These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

690 related items for PubMed ID: 16782727

  • 21. Long-term follow up of patients with multiple myeloma after high-dose chemotherapy and allogeneic stem cell transplantation.
    Rabitsch W, Prinz E, Ackermann J, Wöhrer S, Kaufmann H, Seidl S, Keil F, Kalhs P, Greinix H, Gisslinger H, Leitner G, Drach J.
    Eur J Haematol; 2004 Jan; 72(1):26-31. PubMed ID: 14962259
    [Abstract] [Full Text] [Related]

  • 22. Retrospective analysis of the results of high-dose chemotherapy with the support of autologous blood stem cells in patients with multiple myeloma. The experience of a single centre.
    Kořen J, Spička I, Straub J, Vacková B, Trnková M, Pohlreich D, Pytlík R, Trněný M.
    Prague Med Rep; 2010 Jan; 111(3):207-18. PubMed ID: 20946721
    [Abstract] [Full Text] [Related]

  • 23. Achievement of at least very good partial response is a simple and robust prognostic factor in patients with multiple myeloma treated with high-dose therapy: long-term analysis of the IFM 99-02 and 99-04 Trials.
    Harousseau JL, Avet-Loiseau H, Attal M, Charbonnel C, Garban F, Hulin C, Michallet M, Facon T, Garderet L, Marit G, Ketterer N, Lamy T, Voillat L, Guilhot F, Doyen C, Mathiot C, Moreau P.
    J Clin Oncol; 2009 Dec 01; 27(34):5720-6. PubMed ID: 19826130
    [Abstract] [Full Text] [Related]

  • 24. Autologous or allogeneic stem cell transplantation in patients with Waldenstrom's macroglobulinemia.
    Anagnostopoulos A, Hari PN, Pérez WS, Ballen K, Bashey A, Bredeson CN, Freytes CO, Gale RP, Gertz MA, Gibson J, Goldschmidt H, Lazarus HM, McCarthy PL, Reece DE, Vesole DH, Giralt SA.
    Biol Blood Marrow Transplant; 2006 Aug 01; 12(8):845-54. PubMed ID: 16864055
    [Abstract] [Full Text] [Related]

  • 25. Autologous stem cell transplantation in acute myeloid leukemia. Factors influencing outcome. A 13 year single institution experience.
    Martins C, Lacerda JF, Lourenço F, Carmo JA, Lacerda JM.
    Acta Med Port; 2005 Aug 01; 18(5):329-37. PubMed ID: 16611537
    [Abstract] [Full Text] [Related]

  • 26. Autologous stem cell transplantation after first remission induction treatment in multiple myeloma. A report of the French Registry on Autologous Transplantation in Multiple Myeloma.
    Harousseau JL, Attal M, Divine M, Marit G, Leblond V, Stoppa AM, Bourhis JH, Caillot D, Boasson M, Abgrall JF.
    Stem Cells; 1995 Aug 01; 13 Suppl 2():132-9. PubMed ID: 8520502
    [Abstract] [Full Text] [Related]

  • 27. Long-term outcome of autologous stem cell transplantation in light chain deposition disease.
    Lorenz EC, Gertz MA, Fervenza FC, Dispenzieri A, Lacy MQ, Hayman SR, Gastineau DA, Leung N.
    Nephrol Dial Transplant; 2008 Jun 01; 23(6):2052-7. PubMed ID: 18178602
    [Abstract] [Full Text] [Related]

  • 28. BU and CY as conditioning regimen for autologous transplant in patients with multiple myeloma.
    Talamo G, Claxton DF, Dougherty DW, Ehmann CW, Sivik J, Drabick JJ, Rybka W.
    Bone Marrow Transplant; 2009 Aug 01; 44(3):157-61. PubMed ID: 19204716
    [Abstract] [Full Text] [Related]

  • 29. Simple variables predict survival after autologous transplantation: a single centre experience in 181 multiple myeloma patients.
    Krejci M, Hajek R, Buchler T, Krivanova A, Svobodnik A, Pour L, Adam Z, Mayer J, Vorlicek J.
    Neoplasma; 2007 Aug 01; 54(2):143-8. PubMed ID: 17319788
    [Abstract] [Full Text] [Related]

  • 30. Partially T-cell-depleted allogeneic stem-cell transplantation for first-line treatment of multiple myeloma: a prospective evaluation of patients treated in the phase III study HOVON 24 MM.
    Lokhorst HM, Segeren CM, Verdonck LF, van der Holt B, Raymakers R, van Oers MH, Barge RM, Schouten HC, Westveer PH, Steijaert MM, Cornelissen JJ, Sonneveld P, Dutch-Belgian Hemato-Oncology Cooperative Group.
    J Clin Oncol; 2003 May 01; 21(9):1728-33. PubMed ID: 12721248
    [Abstract] [Full Text] [Related]

  • 31. Second autologous or allogeneic transplantation after the failure of first autograft in patients with multiple myeloma.
    Qazilbash MH, Saliba R, De Lima M, Hosing C, Couriel D, Aleman A, Roden L, Champlin R, Giralt SA.
    Cancer; 2006 Mar 01; 106(5):1084-9. PubMed ID: 16456814
    [Abstract] [Full Text] [Related]

  • 32. High-dose therapy and autologous stem cell transplantation in patients with diffuse large B-cell lymphoma in first complete or partial remission.
    Papajik T, Raida L, Faber E, Vondrakova J, Prochazka V, Kubova Z, Skoumalova I, Jarosova M, M LK, Paucek B, Myslivecek M, Neoral C, Oral I, Jarkovsky J, Dusek L, Indrak K.
    Neoplasma; 2008 Mar 01; 55(3):215-21. PubMed ID: 18348654
    [Abstract] [Full Text] [Related]

  • 33. High-dose therapy and autologous peripheral blood stem cells transplantation followed by a very low reduced intensity regimen with fludarabine + cyclophosphamide and allograft improve complete remission rate in de novo multiple myeloma patients.
    Martino M, Console G, Irrera G, Praticò G, Stelitano C, Callea V, Morabito F, Quartarone E, Musolino C, Piro E, Brugiatelli M, Iacopino P.
    Am J Hematol; 2006 Dec 01; 81(12):973-8. PubMed ID: 16888786
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Prognostic factors for survival after autologous transplantation: a single centre experience in 133 multiple myeloma patients.
    Krejci M, Buchler T, Hajek R, Svobodnik A, Krivanova A, Pour L, Adam Z, Mayer J, Vorlicek J.
    Bone Marrow Transplant; 2005 Jan 01; 35(2):159-64. PubMed ID: 15543200
    [Abstract] [Full Text] [Related]

  • 40. Comparison of high-dose melphalan with a more intensive regimen of thiotepa, busulfan, and cyclophosphamide for patients with multiple myeloma.
    Anagnostopoulos A, Aleman A, Ayers G, Donato M, Champlin R, Weber D, Alexanian R, Giralt S.
    Cancer; 2004 Jun 15; 100(12):2607-12. PubMed ID: 15197803
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 35.